Compositions for elastogenesis and connective tissue treatment
View Patent ↗The present invention describes therapeutic compositions comprising one or more minerals, including trivalent iron, divalent manganese and salts thereof, suitable in facilitating synthesis and deposition of connective tissue matrix, particularly rich of elastin and collagen, and mitogenic potential in human dermal fibroblasts. It also describes the phenomenon in which stimulation of elastogenesis by arterial SMC associates with a net decrease in proliferation of these cell types. The present invention also describes methods of treatment of human skin fibroblasts and arterial smooth muscle cells. The therapeutic compositions of the present invention comprise one or more of trivalent iron or divalent manganese or salts thereof and may be combined with an elastic tissue digest.
1. A method of inducing elastin production at a tissue site comprising scar tissue, visible lines or wrinkles comprising administering to a site in need thereof on a mammal an effective amount of a therapeutic composition comprising about 5 to about 75 μM of a trivalent iron based compound and a GXXPG peptide having a sequence selected from the group consisting of GAAPG (SEQ ID NO: 1), GVVPG (SEQ ID NO: 2), GGGPG (SEQ ID NO: 3), GLLPG (SEQ ID NO: 4), GIIPG (SEQ ID NO: 5), GSSPG (SEQ ID NO: 6), GTTPG (SEQ ID NO: 7), GCCPG (SEQ ID NO: 8), GMMPG (SEQ ID NO: 9), GFFPG (SEQ ID NO: 10), GYYPG (SEQ ID NO: 11), GWWPG (SEQ ID NO: 12), GDDPG (SEQ ID NO: 13), GNNPG (SEQ ID NO: 14), GEEPG (SEQ ID NO: 15), GQQPG (SEQ ID NO: 16), GRRPG (SEQ ID NO: 17), GHHPG (SEQ ID NO: 18), GKKPG (SEQ ID NO: 19), GPPPG (SEQ ID NO: 20), G3Hyp3HypPG (SEQ ID NO: 21) and G4Hyp4HypPG (SEQ ID NO: 22).
2. The method of claim 1 , wherein the trivalent iron based compound is ferric ammonium citrate.
3. The method of claim 1 , wherein the trivalent iron based compound is ferric chloride.
4. The method of claim 1 , wherein the therapeutic composition further comprises an excipient.
5. The method of claim 1 , wherein the therapeutic composition is selected from the group consisting of an emulsion, a lotion, a spray, an aerosol, a powder, an ointment, a cream, a mouthwash, a toothpaste, a foam and a gel.
6. The method of claim 1 , wherein the therapeutic composition further comprises retinoic acid.
7. The method of claim 1 , wherein the therapeutic composition further comprises a divalent manganese based compound.
8. The method of claim 1 , wherein the therapeutic composition is administered to the mammal topically.
9. The method of claim 1 , wherein the trivalent iron based compound has a concentration of about 5 to about 50 μM.
10. The method of claim 1 , wherein the trivalent iron based compound has a concentration of 2 μM.
11. A method of inducing elastin production at a tissue site comprising administering an effective amount of a therapeutic composition comprising 2 μM of a trivalent iron based compound and a GXXPG peptide having a sequence selected from the group consisting of GAAPG (SEQ ID NO: 1), GVVPG (SEQ II) NO: 2), GGGPG (SEQ ID NO: 3), GLLPG (SEQ ID NO: 4), GIIPG (SEQ ID NO: 5), GSSPG (SEQ ID NO: 6), GTTPG (SEQ ID NO: 7), GCCPG (SEQ ID NO: 8), (GMMPG (SEQ ID NO: 9), GFFPG (SEQ ID NO: 10), GYYPG (SEQ ID NO: 11), GWWPG (SEQ ID NO: 12), GDDPG (SEQ ID NO: 13), GNNPG (SEQ ID NO: 14), GEEPG (SEQ ID NO: 15), GQQPG (SEQ ID NO: 16), GRRPG (SEQ ID NO: 17), GHHPG (SEQ ID NO: 18), GKKPG (SEQ ID NO: 19), GPPPG (SEQ ID NO: 20), G3Hyp3HypPG (SEQ ID NO: 21) and G4Hyp4HypPG (SEQ ID NO: 22).
12. The method of claim 11 , wherein the trivalent iron based compound is ferric ammonium citrate.
13. The method of claim 11 , wherein the trivalent iron based compound is ferric chloride.
14. The method of claim 11 , wherein the therapeutic composition further comprises an excipient.
15. The method of claim 11 , wherein the therapeutic composition is selected from the group consisting of an emulsion, a lotion, a spray, an aerosol, a powder, an ointment, a cream, a mouthwash, a toothpaste, a foam and a gel.
16. The method of claim 11 , wherein the therapeutic composition further comprises retinoic acid.
17. The method of claim 11 wherein the therapeutic composition further comprises a divalent manganese based compound.
18. The method of claim 11 , wherein the therapeutic composition is administered to the mammal topically.